2022
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
Shafi S, Aung T, Xirou V, Gavrielatou N, Vathiotis I, Fernandez A, Moutafi M, Yaghoobi V, Herbst R, Liu L, Langermann S, Rimm D. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 36775354, DOI: 10.1038/s41374-022-00796-6.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsHumansLungLung NeoplasmsProgrammed Cell Death 1 ReceptorSialic Acid Binding Immunoglobulin-like LectinsSquamous Cell Carcinoma of Head and NeckUrinary Bladder NeoplasmsConceptsSiglec-15 expressionNon-small cell lung cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaCancer typesOverall survivalCell carcinomaBladder cancerImmune cellsSiglec-15PD-1/PD-L1 blockadePotential future clinical trialsQuantitative immunofluorescencePD-L1 blockadeStromal immune cellsImmune checkpoint blockadeCell lung cancerFuture clinical trialsNew potential targetsCheckpoint blockadePD-L1Lung cancerClinical trialsIntra-tumoral heterogeneityQuantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer
Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 35581307, PMCID: PMC10211373, DOI: 10.1038/s41374-022-00796-6.Peer-Reviewed Original ResearchConceptsSiglec-15 expressionNon-small cell lung cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaCancer typesOverall survivalCell carcinomaBladder cancerImmune cellsSiglec-15PD-1/PD-L1 blockadePotential future clinical trialsQuantitative immunofluorescencePD-L1 blockadeStromal immune cellsImmune checkpoint blockadeCell lung cancerFuture clinical trialsNew potential targetsCheckpoint blockadePD-L1Lung cancerClinical trialsIntra-tumoral heterogeneity
2015
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Journal Of Clinical Investigation 2015, 126: 169-180. PMID: 26619122, PMCID: PMC4701554, DOI: 10.1172/jci82066.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellDasatinibDiscoidin Domain ReceptorsFemaleHead and Neck NeoplasmsHumansInositol 1,4,5-Trisphosphate ReceptorsLymphatic MetastasisMaleMiddle AgedMutationNeoplasm Recurrence, LocalReceptor Protein-Tyrosine KinasesReceptors, MitogenSquamous Cell Carcinoma of Head and NeckConceptsDiscoidin domain receptor tyrosine kinase 2Neck squamous cell carcinomaSquamous cell carcinomaRecurrent tumorsWhole-exome sequencingSynchronous lymphCell carcinomaPrimary tumorDDR2 mutationsTumor pairsSrc family kinase inhibitorRecurrent/metastatic HNSCCPrimary index tumorSynchronous nodal metastasesHalf of patientsReceptor tyrosine kinase 2Tyrosine kinase 2American Cancer SocietyIndex primary tumorPotential therapeutic targetPrecision medicine approachLong-term survivalRespective primary tumorsSomatic nucleotide variantsNational Cancer Institute